

New robust and selective sensor surfaces - new publication using Attana's QCM-technology

Prof Nicholls and co-workers at the Linnaeus University has in a recent publication presented results showing development of a new robust and selective biosensors surface based on polymer nanowire films. The concept demonstrates high selectivity, sensitivity and accessibility towards a given analyte molecule. Attana's QCM technology has been applied both for the development and to demonstrate the capability of the sensor surfaces.

In the [article](#) the performance of different versions of functionalized nanowires are presented. The nanowires are manufactured using molecular imprinted polymers and size and functionalization are systematically varied in order to determine optimal sensing properties for a given environment. Parameters such as robustness, selectivity, sensitivity and kinetic response time was characterized. As analyte molecule different versions of biotin molecules were used. Biotin is a well known molecule and hence suitable for benchmarking. A potential application for the sensor surfaces would be capturing of biotinylated or histidine tag molecules since they are frequently used in purification and characterization processes for the development and manufacturing of biopharmaceuticals.

This work is performed as part of the Swedish Knowledge Foundation financed project "["BIO-QC: Quality Control and Purification for New Biological Drugs"](#)" (grant number 20170059), where Attana is part. This is the second publication involving Attana's technology from the project. [The first publication](#) is about improved experimental data analysis and the two publications follows the project plan in developing a full concept for quality control and purifications of new biological pharmaceuticals.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of *in-vitro* characterization of molecular interactions mimicking *in-vivo* conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana's products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana's contract research services and our label free cell-based biosensors, please visit www.attana.com or contact sales@attana.com.